Evidence-Based Review of Tibolone and Oestrogen-Based Hormone Replacement Therapy

1. Hope S Wager E Rees MCP Survey of British women's views on the menopause and HRT. J Br Meno Soc. 1998; 4: 33–36.

2. Moore RA . Livial: a review of clinical studies. Br J Obstet Gynaecol 1999; 106(suppl 19): 1–21.

3. Dolan P Torgerson DJ The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporosis Int 1998; 8: 611–617.

4. Lippuner K Haenggi W Birkhauser MJ Jaeger P. Prevention of postmenopausal bone loss using tibolone, conventional peroral or transdermal replacement therapy. J Bone Miner Res 1997; 12: 806–12.

5. Grady D Gebretsadik T Kerlikowske K Ernster V Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304–313

6. Markiewicz L Gurpide E. In-vitro evaluation of oestrogenic, oestrogen antagonist and progestogenic effects of a steroidal drug (Org OD14) and its metabolites on human endometrium. J Steroid Biochem 1990; 35: 5525–41.

7. Tang B Markiewicz L Kloosterboer HJ . Human endometrial 3-β OH steroid dehydrogenase/isomerase can locally produce intrinsic oestrogenic/progestogenic activity ratios of a steroidal drug (ORG OD14). J Steroid Biochem Molec Biol 1993; 45: 345–51.

8. Johannes E. Tibolone: vaginal bleeding and the specific endometrial response in postmenopausal women. Gynecol Endrocrinol 1997; 2(S2): 25–30

9. Hammar M Christau S Nathorst-Boos J Rud T Garre K. A double-blind, randomised trial comparing the effects of tibolone in continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998; 105: 904–11.

10. von Dadelszen P Gillmer MDG Gray MD Endometrial hyperplasia and adenocarcinoma during tibolone therapy. Br J Obstet Gynaecol 1994; 101: 158–161.

11. Collaborative Group on Hormonal Factors in Breast Cancer . Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350: 1047–59.

12. Erel CT Elter K Akman C . Mammographic changes in women receiving tibolone therapy. Fertil Steril 1998; 69: 870–75

13. Newton J. The epidemiology of coronary heart disease and HRT: what are the contentious issues? J Br Meno Soc 1998; 4: 135–142.

14. Cagnacci A Mallus E Tuveri F Cirillo R Setteneri AM Melis GB . Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1997; 82: 251–3.

15. Rymer J Crook D Sidhu M . Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol 1993; 128: 25–62.

16. Bjarnason NH Bjarnason K Haarbo J Coelingh-Bennink HJ Christenson C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997; 82: 175–6.

17. Rosati D Micheli S Pinto S . Changes in lipidic and haemostatic parameters induced by tibolone treatment. Thromb Res 1997; 85: 273–8